171 related articles for article (PubMed ID: 35490395)
1. An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis.
Werfel T; Irvine AD; Bangert C; Seneschal J; Grond S; Cardillo T; Brinker D; Zhong J; Riedl E; Wollenberg A
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1486-1496. PubMed ID: 35490395
[TBL] [Abstract][Full Text] [Related]
2. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
3. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
Bieber T; Thyssen JP; Reich K; Simpson EL; Katoh N; Torrelo A; De Bruin-Weller M; Thaci D; Bissonnette R; Gooderham M; Weisman J; Nunes F; Brinker D; Issa M; Holzwarth K; Gamalo M; Riedl E; Janes J
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):476-485. PubMed ID: 32926462
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
5. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T; Katoh N; Simpson EL; de Bruin-Weller M; Thaçi D; Torrelo A; Sontag A; Grond S; Issa M; Lu X; Cardillo T; Holzwarth K; Thyssen JP
J Dermatolog Treat; 2023 Dec; 34(1):2161812. PubMed ID: 36546346
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
[TBL] [Abstract][Full Text] [Related]
7. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
8. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
[TBL] [Abstract][Full Text] [Related]
10. Infectious adverse events in patients with atopic dermatitis treated with baricitinib.
Antonelli F; Malvaso D; Caldarola G; Simone C; Peris K; Chiricozzi A
Immunotherapy; 2023 Dec; 15(18):1521-1529. PubMed ID: 37850366
[TBL] [Abstract][Full Text] [Related]
11. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
Simpson EL; Bissonnette R; Paller AS; King B; Silverberg JI; Reich K; Thyssen JP; Doll H; Sun L; DeLozier AM; Nunes FP; Eichenfield LF
Br J Dermatol; 2022 Oct; 187(4):531-538. PubMed ID: 35442530
[TBL] [Abstract][Full Text] [Related]
12. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract][Full Text] [Related]
13. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
[TBL] [Abstract][Full Text] [Related]
14. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Silverberg JI; Simpson EL; Wollenberg A; Bissonnette R; Kabashima K; DeLozier AM; Sun L; Cardillo T; Nunes FP; Reich K
JAMA Dermatol; 2021 Jun; 157(6):691-699. PubMed ID: 33978711
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
16. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
[TBL] [Abstract][Full Text] [Related]
17. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
18. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials.
Katoh N; Takita Y; Isaka Y; Nishikawa A; Torisu-Itakura H; Saeki H
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2765-2779. PubMed ID: 36255569
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
20. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
